; (B) detail the requirements for maintaining the Reserve described in subsection (c), including— (i) storage and testing requirements, consistent with parts 210 and 211 of title 21, Code of Federal Regulations, or any successor regulation; and (ii) any specific criteria agreed to by the Secretary and the manufacturer of the essential generic medicine using the active pharmaceutical ingredient or key starting material; (C) be designed to minimize the impact of any interruption or reduction in imports of— (i) active pharmaceutical ingredients and other key starting materials that the Secretary determines are, or are likely to become, dependent upon such imports for a substantial portion of finished essential generic medicines; and (ii) finished dosage forms of essential generic medicines for which active pharmaceutical ingredients and other key starting materials are not imported; (D) include provisions to strengthen domestic capacity for active pharmaceutical ingredient production, storage, and conversion; and (E) outline plans and processes for coordinating and consulting, as appropriate, with the Assistant Secretary for Preparedness and Response regarding relevant issues of interest pertaining to the maintenance and stocking of the strategic national stockpile. (2) Required components (A) In general The Plan shall include the following: (i) Identification and prioritization of the essential generic medicines included on the most recent list under section 319N(a)— (I) that the Secretary determines are essential for health care needs in the United States; and (II) for which the Secretary determines that there is the greatest need to maintain a reserve of the active pharmaceutical ingredients and key starting materials for the essential generic medicines— (aa) taking into account factors including the extent to which the United States is, or is at risk of becoming, dependent on foreign sources for a substantial portion of the domestic need